Riskpilot← Back to searchSign inGet full accessROSENBORG APOTEK AS
ASActiveOrg 924706961Stadsing Dahls gate 5, 7015 TrondheimRetail sale of pharmaceutical products · NACE 4773Est. 20206 employees
Revenue 2024
NOK 19,6M
+14% vs 2023
EBITDA margin
8.5%
-2% vs 2023
Equity ratio
15.4%
Financial strength
Net profit 2024
NOK 1,1M
0% vs 2023
| Revenue | NOK 19,6M | +14% |
| EBITDA | NOK 1,7M | -2% |
| Net profit | NOK 1,1M | +0% |
| Total assets | NOK 5M | -17% |
| Equity | NOK 771K | +4% |
| Employees | 6 | — |
Legal name
ROSENBORG APOTEK AS
Org number
924706961
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
17. mars 2020
Share capital
NOK 705 000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Eie og drive apotek og annet som naturlig faller sammen med dette.
Address
Stadsing Dahls gate 5, 7015 Trondheim
Phone
+4773505077
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 235 | 10 335 | 12 740 | 17 247 | 19 623 |
| Staff expenses | −473 | −1 812 | −1 895 | −2 076 | −2 803 |
| EBITDA | −70 | 835 | 885 | 1 704 | 1 666 |
| Depreciation & amort. | −47 | −197 | −197 | −197 | −197 |
| EBIT | −118 | 637 | 688 | 1 507 | 1 469 |
| Net financials | −44 | −73 | −54 | −57 | −16 |
| Profit before tax | −162 | 564 | 634 | 1 450 | 1 453 |
| Tax | −37 | 124 | 140 | 319 | 321 |
| Net profit | −125 | 440 | 495 | 1 130 | 1 132 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 687 | 4 993 | 4 520 | 6 053 | 5 011 |
| Equity | 574 | 1 014 | 1 509 | 739 | 771 |
| Long-term debt | 1 350 | 1 437 | 1 242 | 1 009 | 767 |
| Short-term debt | 1 763 | 2 541 | 1 769 | 4 306 | 3 473 |
| Total debt | 3 113 | 3 978 | 3 011 | 5 314 | 4 240 |
EBITDA margin
8.5%
This company
15.8%
Market median
-46% vs market
20202024
Equity ratio
15.4%
This company
38.2%
Market median
-60% vs market
20202024
Return on equity
146.8%
This company
18.4%
Market median
+698% vs market
20202024
Net profit margin
5.8%
This company
8.1%
Market median
-28% vs market
20202024
Asset turnover
3.92×
This company
1.12×
Market median
+250% vs market
20202024
Debt / equity
5.50×
This company
0.62×
Market median
-787% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-02-11 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FS Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
VS Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Chairman | 2021 | |
| Former (1) | ||
| Chairman | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 45.82% | 45.82% | 2022 | |
| Company | 45.82% | 45.82% | 2022 | |
| Company | 8.37% | 8.37% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fsloe As
ROSENBORG APOTEK AS Board members of ROSENBORG APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vegar Sellæg Brenne | Chief Executive Officer | 0 companies |
| Fredrik Sandberg Løding | Chief Executive Officer | 0 companies |
| Lars Kristian Myhre | Chairman | 0 companies |
| Vegar Sellæg | Board of Directors | 0 companies |
| Jon Torstein Woll | Chairman | 0 companies |